New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
NCT ID NCT05907759
First seen Feb 18, 2026 · Last updated Jun 20, 2026 · Updated 23 times
Summary
This phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab is given as a shot under the skin weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks for up to 2 years. The main goal is to see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KSHV ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab (a drug that targets a protein on cancer cells)
What this could lead to
If it works, this could offer a new treatment option for people with these rare, hard-to-treat blood cancers.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects like infusion reactions or infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.